

## **“Hyperkalemia in CKD and HFrEF...What Am I Missing?”**

### **OPAL-HK**

#### **Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors**

Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. *N Engl J Med*. 2015;372(3):211-221. doi:10.1056/NEJMoa1410853

Link: <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1410853?articleTools=true>

### **DIAMOND Trial**

#### **Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial**

Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. *Eur Heart J*. 2022;43(41):4362-4373. doi:10.1093/eurheartj/ehac401

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622299/pdf/ehac401.pdf>

### **Potassium Binders in Dialysis Patients**

Bushinsky DA, Rossignol P, Spiegel DM, et al. Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis. *Am J Nephrol*. 2016;44(5):404-410. doi:10.1159/000451067

Link: <https://karger.com/ajn/article-pdf/44/5/404/2210649/000451067.pdf>

### **Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients**

Kovesdy CP, Rowan CG, Conrad A, Spiegel DM, Fogli J, Oestreicher N, Connaire JJ, Winkelmayr WC. Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients. *Kidney Int Rep*. 2018 Oct 29;4(2):301-309. doi: 10.1016/j.ekir.2018.10.020.

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365398/pdf/main.pdf>

### **2023 Guideline Update**

#### **2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure**

McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published online ahead of print, 2023 Aug 25]. *Eur Heart J*. 2023;ehad195.

Link: <https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehad195/51174375/ehad195.pdf>

## **Guidelines**

### **KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease**

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int.* 2022;102(5S):S1-S127. doi:10.1016/j.kint.2022.06.008

Link: <https://www.kidney-international.org/action/showPdf?pii=S0085-2538%2822%2900507-5>

### **KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.**

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int.* 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003.

Link: <https://www.kidney-international.org/action/showPdf?pii=S0085-2538%2820%2931270-9>

### **Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes**

Collins AJ, Pitt B, Reaven N, et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. *Am J Nephrol.* 2017;46(3):213-221. doi:10.1159/000479802

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637309/>